The Role of Oxytocin in MDMA’s Prosocial Effects
The link between oxytocin and MDMA is less straightforward than once thought.
Clinical Trials - Page 2
First Modern Dose-Response Study of LSD Confirms the Critical Role of the Serotonin 2A Receptor
Escalating LSD doses lead to more pronounced subjective and autonomic effects, while pre-administration of ketanserin prevents the effects of a high LSD dose.
Pilot Study of Psilocybin-Assisted Group Therapy in Older AIDS Survivors
Feasibility, safety, and potential efficacy of psilocybin-assisted group therapy was demonstrated in treating demoralization in this marginalized population.
Low-Dose LSD Reduces Pain Perception
A new clinical study reports that 20µg of LSD significantly reduces pain perception. This promising investigation builds on the little-known history of research into LSD as a potential analgesic.
Cybin’s Sublingual Psilocybin Strips Head to Clinical Trials for Dose-Finding
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
MindMed and Liechti Lab to Conduct the First Clinical Trial Combining LSD and MDMA
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
The Mystical Experience is Critical for the Therapeutic Effects of Psilocybin
Two studies indicate that higher doses of psilocybin are necessary for sustained reductions in depression and anxiety.
The Growing Evidence for Psilocybin-Facilitated Smoking Cessation
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
LSD and Psilocybin May Alleviate Cluster Headaches
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.
Psilocybin to Treat Anxiety and Depression in Cancer Patients
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.